No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Sezary syndrome

被引：21

作者：

Lundin, J ^{[1
]}

Kennedy, B ^{[1
]}

Dearden, C ^{[1
]}

Dyer, MJS ^{[1
]}

Österborg, A ^{[1
]}

机构：

[1] Karolinska Hosp, Dept Oncol, SE-17176 Stockholm, Sweden

来源：

BLOOD | 2005年 / 105卷 / 10期

关键词：

D O I：

10.1182/blood-2004-11-4314

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：4148 / 4149

页数：2

共 4 条

[1] A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas [J].

Enblad, G ;

Hagberg, H ;

Erlanson, M ;

Lundin, J ;

MacDonald, AP ;

Repp, R ;

Schetelig, J ;

Seipelt, G ;

Österborg, A .

BLOOD, 2004, 103 (08) :2920-2924

[2] Treatment of patients with advanced mycosis fungoides and Sezary syndrome with alemtuzumab [J].

Kennedy, GA ;

Seymour, JF ;

Wolf, M ;

Januszewicz, H ;

Davison, J ;

McCormack, C ;

Ryan, G ;

Prince, HM .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2003, 71 (04) :250-256

[3] Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sezary syndrome [J].

Lenihan, DJ ;

Alencar, AJ ;

Yang, D ;

Kurzrock, R ;

Keating, MJ ;

Duvic, M .

BLOOD, 2004, 104 (03) :655-658

[4] Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome [J].

Lundin, J ;

Hagberg, H ;

Repp, R ;

Cavallin-Stahl, E ;

Fredén, S ;

Juliusson, G ;

Rosenblad, E ;

Tjonnfjord, G ;

Wiklund, T ;

Österborg, A .

BLOOD, 2003, 101 (11) :4267-4272

← 1 →